Table 2

EGFR Positivity by Study Subgroup
Characteristic, n = 357 EGFR neg EGFR pos P
(score 0) (score 1-3+) Value
n (%) n (%)
Female, 143 79 (55) 64 (45)
Male, 214 126 (59) 88 (41) .69
Age,
>65, 173 96 (55) 77 (45)
≤65, 181 107 (59) 74 (41) .698
ECOG performance status,
0-1, 326 186 (57) 140 (43)
2, 22 11 (50) 11 (50) .697
Not specified, 9 8 (89) 1 (11)
Primary tumor location
Gastroesophageal junction, 107 60 (56) 47 (44)
Mid to distal stomach, 231 132 (57) 99 (43) .916
Not specified, 19 13 (68) 6 (32)
Disease status
Stage IV at diagnosis, 298 171 (57) 127 (43)
Recurrent disease, 59 34 (58) 25 (42) 1
Metastatic disease sites
Liver, present, 157 85 (54) 72 (46)
Liver, not present, 199 119 (60) 80 (40) .559
Lymph nodes, present 219 127 (58) 92 (42)
Lymph nodes, not present, 98 51 (52) 47 (48) .585
Peritoneum, present ,93 57 (61) 36 (39)
Peritoneum, not present, 263 147 (56) 116 (44) .58
Lauren classification,
Diffuse/mixed, 170 107 (63) 63 (37) .211
Intestinal, 139 72 (52) 67 (48)
Not specified, 48 26 (54) 22 (46)
Specimen used for EGFR testing
Biopsy, 238 141 (59) 97 (41)
Surgical specimen,116 62 (53) 54 (47) .538
Not specified, 3 2 (67) 1 (33)
Primary tumor, 298 173 (58) 125 (42)
Metastatic lesion, 50 24 (48) 26 (52) .418
Not specified, 9 9 (100) 0

Atmaca et al.

Atmaca et al. BMC Cancer 2012 12:524   doi:10.1186/1471-2407-12-524

Open Data